Health experts concerned about decision not to extend Daklinza treatment to patients with genotype 3 strain of virus
Thousands of people in England with a chronic form of liver disease
are being denied access to life-saving drugs that are available to
patients in Wales, Scotland and Northern Ireland.
Despite being recommended by European regulators and available in
countries such as France and Germany, draft guidance recently issued by
the National Institute for Health and Care Excellence (Nice),
the body that advises NHS England on whether to fund certain drugs,
recommends restricting the use of Daklinza in England. The stance will
affect the treatment of adult patients with a particular strain of
The move has dismayed health experts and liver disease charities who
say it will mean a large subset of the sickest and most at risk patients
in England will not receive the treatment they need to prevent them
from potentially fatal liver failure or cancer.
Labels: acces to treatment, Daklinza, NHS, UK